Anticancer drug reveals alternate means of inducing cell suicide

Derivatives of the COX-2 inhibitor celecoxib can trigger cancer cell suicide, or apoptosis, but not necessarily through the recognized means of blocking COX-2 enzyme activity, a new study concludes. By separating COX-2 activity from apoptosis, researchers have a starting point for designing new classes of anticancer drugs, write Xueqin Song, Ching-Shih Chen, Ph.D., Ohio State University, and their coworkers in the April 17 issue of the Journal of the National Cancer Institute.

Celecoxib, an anti-inflammation pill for arthritis, is being studied for its potential in preventing and treating certain cancers. In a large percentage of tumors, the COX-2 enzyme is elevated, say Ernest T. Hawk, M.D., M.P.H., of the National Cancer Institute, and his coworkers in an accompanying editorial. They point out that past studies have shown that decreasing levels of COX-2 can suppress the growth of tumors. However, it has been unclear whether celecoxibs anticancer effects depend on COX-2 inhibition alone.

To find out, Chen and his coworkers created prostate cancer cells lacking the COX-2 enzyme. In contrast to the effects of COX-2 inhibitors such as celecoxib, which induce cell death, cells that lacked COX-2 remained alive. Exposure of these cells lacking COX-2 to various COX-2 inhibitors did lead to cell death. Whats more, derivatives of celecoxib that did not block COX-2 activity also caused cell death.

The authors note that these events were associated not with levels of COX-2 but with decreased phosphorylation of Akt and ERK2 proteins. This mode of action differs from that of conventional anticancer drugs, they point out.

In the accompanying editorial, Hawk and his colleagues note that celecoxib is being tested for the treatment and prevention of colon cancer and that newer generations of COX-2 inhibitors could prove to be safer and more effective.

However, they point out that the current findings are based on concentrations of c

Contact: Linda Wang
Journal of the National Cancer Institute

Page: 1 2

Related biology news :

1. Anticancer drug zebularine specifically targets tumor cells
2. The Bodys Anticancer Weaponry Backfires In Old Age
3. Enzymes "Magic" May Hold Key to Anticancer and Antimicrobial Drugs
4. Hidden diversity: DNA barcoding reveals a common butterfly is actually 10 different species
5. Brown research reveals key insight into memory-making
6. Study reveals why eyes in some paintings seem to follow viewers
7. New dye directly reveals activated proteins in living cells
8. Study reveals first genetic step necessary for prostate cancer growth
9. Study of flu patients reveals virus outsmarting key drug
10. Study in Science reveals recreational fishing takes big bite of ocean catch
11. Plumbing trees plumbing reveals their engineering skill

Post Your Comments:

(Date:11/18/2015)... Nov. 18, 2015  As new scientific discoveries deepen ... and other healthcare providers face challenges in better using ... patients. In addition, as more children continue to survive ... adulthood and old age. John M. Maris, ... Hospital of Philadelphia (CHOP) . --> ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... www.aezsinc.com . --> Aeterna Zentaris is a ...
Breaking Biology Technology:
Cached News: